Patents for A61P 35 - Antineoplastic agents (221,099)
04/2002
04/17/2002EP1196773A1 E4orf4 and pp2a polypeptides, modulators, and mimetics for selectively inducing cell death
04/17/2002EP1196638A1 USE OF THE i KRIT1 /i GENE IN ANGIOGENESIS
04/17/2002EP1196635A2 Cell death related drug targets in yeast and fungi
04/17/2002EP1196616A2 Replication-competent anti-cancer vectors
04/17/2002EP1196598A1 Dsp-3 dual-specificity phosphatase
04/17/2002EP1196595A2 Methods of inducing cell death
04/17/2002EP1196579A2 Tryptase inhibitor
04/17/2002EP1196577A2 Cell cycle and proliferation proteins
04/17/2002EP1196574A2 Human proteins involved in detoxification
04/17/2002EP1196569A2 Electron transfer proteins
04/17/2002EP1196568A1 Human lim domain proteins
04/17/2002EP1196567A2 Human immune response molecules
04/17/2002EP1196565A2 Compositions and methods for the therapy and diagnosis of lung cancer
04/17/2002EP1196560A1 Neurotrophic factor receptor gfr-alpha-4
04/17/2002EP1196443A2 Erythropoietin conjugates with polyethylenglycol
04/17/2002EP1196441A1 Keratinocyte growth factor-2
04/17/2002EP1196440A2 Therapeutic peptides derived from subsequences of bpi
04/17/2002EP1196435A1 Recombinant adenovirus
04/17/2002EP1196433A2 CYCLIC PEPTIDE DERIVATIVES AS INHIBITORS OF INTEGRIN ALPHA v BETA 6
04/17/2002EP1196428A1 11$g(b)-ARYL-17,17-SPIROTHIOLANE-SUBSTITUTED STEROIDS
04/17/2002EP1196427A2 Novel c-19-halogen-substituted steroids of the androst-9(11)-ene-series, methods for the production and use thereof
04/17/2002EP1196419A1 Potassium channel blocking agents
04/17/2002EP1196407A1 N-imidazolylmethyl carboxamides as nitric oxide production inhibitors
04/17/2002EP1196406A1 Amino ceramide-like compounds and therapeutic methods of use
04/17/2002EP1196394A1 Novel carboxylic acid derivatives with 5,6 substituted pyrimidine ring, the production and utilization thereof as endothelin receptor antagonists
04/17/2002EP1196390A2 Pyrazole compositions useful as inhibitors of erk
04/17/2002EP1196193A2 Interleukin-1 muteins useful as vaccine adjuvants
04/17/2002EP1196191A1 Death domain containing receptor 5
04/17/2002EP1196186A2 Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
04/17/2002EP1196169A1 Compounds having cytokine inhibitory activity
04/17/2002EP1196162A1 Procyanidin oligomers for inhibiting matrix metalloproteinases and medicine having effective composition of same
04/17/2002EP1196144A2 A liposome composition having resistance to freeze/thaw damage
04/17/2002EP1196047A1 Prophylactic dietary supplement based on milk
04/17/2002EP1196043A1 An effervescent green tea extract formulation
04/17/2002EP1019037B9 Medicament containing delta-aminolevulinic acid
04/17/2002EP0937038B1 Vitamin d analogues
04/17/2002EP0902783B1 Hydrolysis-promoting taxane hydrophobic derivatives
04/17/2002EP0901378B1 Pharmaceutical compositions containing cyclosporine and a carrier comprising at least an ester of alpha-glycerophosphoric acid
04/17/2002EP0662827B1 Diagnostic methods and pharmaceutical compositions based on notch proteins and nucleic acids
04/17/2002CN1345374A HER-2/neu fusion proteins
04/17/2002CN1345373A Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase
04/17/2002CN1345334A Antibodies specific to KDR and uses thereof
04/17/2002CN1345331A Method and composition for angiogenesis inhibition
04/17/2002CN1345329A Tumor mecrosis factor receptors 6 alpha and beta
04/17/2002CN1345321A Optically pure camptothecin analogues
04/17/2002CN1345315A Hydroxymatatairesinol in cancer prevention
04/17/2002CN1345312A Dibenzoazulene derivatives for treating thrombosis, osteoporosis arteriosclerosis
04/17/2002CN1345307A N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists
04/17/2002CN1345249A Kit for radiolabeling proteins with yttrium-90
04/17/2002CN1345247A Expression vectors and cell lines expressing vascular endothelial growth factor D, and method of treating melanomas
04/17/2002CN1345246A Compositions and method for prevention or treatment of cancer and bone loss associated with cancer
04/17/2002CN1345242A Method for treatment of leukaemia
04/17/2002CN1345240A Improved cancer treatment with temozolomide
04/17/2002CN1344747A Antitumor carboxyalkyl achyranthis polysaccharide
04/17/2002CN1344746A Prepn and application of individual antitumor specific antibody
04/17/2002CN1344722A Amino polyoligoglucosan with 1-6 connection and glucoside and their synthesis and application
04/17/2002CN1344566A Tumor vaccine constituting method by combining dendritic cell multiplication and chemotaxis factor and suicide gene
04/17/2002CN1344556A Bladder cancer treating Chinese medicine
04/17/2002CN1344553A Cancer preventing combined health yew decoction and its making process
04/17/2002CN1344548A Blood clot dispersing and tumor eliminating capsule
04/17/2002CN1082821C Antibody cojugates
04/17/2002CN1082813C Stabized solutions of platinum (II) antitumor agents
04/16/2002US6372926 17-side chain alkynyl-and 20-oxopregna-derivatives of vitamin D, methods for their production and pharmaceutical compositions thereof
04/16/2002US6372777 Cyclic AMP-specific phosphodiesterase inhibitors
04/16/2002US6372776 Crystalline(−)-3R,4R-trans-7-methoxy-2,2-dimethyl-3-phenyl-4-{4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}chromane, hydrogen maleate
04/16/2002US6372768 2-aminopyridines containing fused ring substituents
04/16/2002US6372767 Benzanilides as potassium channel openers
04/16/2002US6372758 Sulfamato hydroxamic acid metalloprotease inhibitor
04/16/2002US6372754 Drugs for treatment or prevention of depression, anxiety, pain, inflammation, migraine, emesis or postherpic neuralgia.
04/16/2002US6372753 Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
04/16/2002US6372751 Drugs with benzene and pyrimidine rings
04/16/2002US6372747 Farnesyl protein transferase inhibitors
04/16/2002US6372741 Use of CSAID™ compounds as inhibitors of angiogenesis
04/16/2002US6372739 Coumarone derivatives for drugs
04/16/2002US6372738 Cytotoxic agents comprising taxanes and their therapeutic use
04/16/2002US6372731 Vitamin D derivatives with C-25 substituents, process for their preparation, intermediate products and their use in preparing medicaments
04/16/2002US6372726 Methods of cancer treatment using NAALADase inhibitors
04/16/2002US6372719 ανβ3 integrin antagonists in combination with chemotherapeutic agents
04/16/2002US6372490 Nucleic acid encoding the MDM interacting protein
04/16/2002US6372473 Tissue plasminogen activator-like protease
04/16/2002US6372468 Useful in the development of human therapeutics and diagnostic formulations
04/16/2002US6372462 Cultivating a fungi of the basidiomycetes in a submerged culture on nutrient media, isolating the biomass of edible mushrooms from the culture broth, and drying at a range of 40-45 degrees celsius
04/16/2002US6372454 Also vectors, host cells; screening methods for identifying agonists or antagonists of follistatin-3 activity; diagnostic methods for detecting reproductive system and cell differentiation disorders and treating these
04/16/2002US6372441 Detecting the expression of the variable exon v10 in the cd44 gene in a patient or in a sample obtained from a patient, wherein the expression of the variable exon v10 in the cd44 gene indicates hodgkin's lymphomas
04/16/2002US6372431 Mammalian toxicological response markers
04/16/2002US6372267 Cocoa solids prepared by heating, pressing, recovering partially defatted cocoa solids which contain cocoa polyphenols including cocoa procyanidins
04/16/2002US6372263 Extracted from fertilized ovum of a sea water fish or a fresh water fish
04/16/2002US6372262 Serum-derived factor inducing cell differentiation and medical uses thereof
04/16/2002US6372250 Non-invasive gene targeting to the brain
04/16/2002US6372217 Methods for the treatment of CD7+ viral infection with TXU-7-PAP
04/16/2002US6372207 IFNAR2/IFN complex
04/16/2002US6372205 Pharmaceutical compositions containing antibody-enzyme conjugates in combination with prodrugs
04/16/2002CA2355334A1 Pharmaceutical preparations and methods for inhibiting tumors
04/16/2002CA2087414C Arylcycloalkyl derivatives their production and their use
04/16/2002CA2046607C Inhibiting transformation of cells having elevated purine metabolic enzyme activity
04/16/2002CA2009690C Phenylhydrazones, the manufacture thereof and therapeutic and cosmetic compositions prepared therefrom
04/11/2002WO2002029090A1 Subsance inhibiting the binding of signal transducing molecule to kdr/flk-1 phosphorylated at tyrosine at the 1175-position and method of using the same
04/11/2002WO2002029088A2 Highly expressible genes
04/11/2002WO2002029086A2 Nucleic acid sequences differentially expressed in cancer tissue
04/11/2002WO2002029061A2 G-protein coupled receptors